Grants, Research, and Publications
Grants
Through grants, Ideal Option offers supplemental programs and support across the country to provide low barrier access to medication-assisted treatment for individuals with substance use disorder.
Idaho
MAT Expansion
Ideal Option was awarded Idaho’s Response to the Opioid Crisis subgrant from the State of Idaho’s Division of Behavioral Health to expand access to medication-assisted treatment in rural communities using telemedicine-based services. Through a collaboration with the Panhandle Health District, the rural communities of Kellogg and Sandpoint were identified as the locations that would benefit most from expanded access to treatment. In December of 2021, Ideal Option opened the two limited-hours satellite clinics within the Panhandle Health District’s community clinic buildings.
Idaho
Mobile Outreach
The Idaho Department of Health and Welfare (DHW) awarded funding to Ideal Option to establish and operate a mobile outreach vehicle in underserved populations. The vehicle will cover Idaho Falls, Pocatello, and areas within 1-2 hours of these cities. Ideal Option will operate the vehicle to provide the following services:
- HIV/HepC Testing
- STD Testing and Treatment
- Medication-Assisted Treatment
- Care Coordination
New Mexico
Statewide MAT Provider Workgroup
Ideal Option received funding from the New Mexico Department of Health to build overdose prevention capacity as a part of health promotion efforts to enhance local knowledge of problematic substance use, harm reduction, and access to medication-based treatment (MAT) as well as contribute to evaluation of local, regional, and statewide community efforts to help prevent fatal and nonfatal drug overdoses in New Mexico.
Washington
Hub & Spoke
Ideal Option received Washington Health Care Authority (HCA) funding for the Hub & Spoke (H&S) project. Since then, Ideal Option has successfully inducted individuals and coordinated recovery support services for those seeking access to medications for opioid use disorder (MOUD) in Snohomish and Skagit counties. Ideal Option’s network includes partners providing detox, primary care, SUD counseling, mental health counseling and transportation services.
Arkansas
State Opioid Response
Ideal Option was awarded funding from University of Arkansas for Medical Sciences (UAMS) to support the provision of medication-assisted treatment (MAT) for opioid use disorders (OUD) among rural and uninsured or underinsured Arkansans. Support includes MAT intake and follow up appointments for clients with OUD provided by waivered MAT provider, salary support for a peer recovery support specialists to provide support for clients, and medication used as part of MAT.
Oregon
Peer Resource and Infrastructure for MAT Program
Funding from the Central Oregon Health Council will be leveraged to employ a full-time peer navigator and build infrastructure for a sustainable peer program. Peer navigation can help individuals in addiction treatment make new friends and begin to build alternative social networks. The core roles of this peer navigator will include identification, advocacy, practical assistance, healthcare appointment support, emotional and social support, education, referrals, collaboration, evaluation, and support to navigate the healthcare system. This navigation will not be limited to services at Ideal Option. Ideal Option and the peer navigator will assess the needs of each patient and make referrals to other services as appropriate. The peer navigator will assist the patient in navigating the healthcare and social services systems during their induction, treatment, and recovery.
Research
Washington State University
Connected Pharmacy Platform to Improve Adherence to Buprenorphine-Naloxone Prescription Treatment of Opioid Use Disorder
The purpose of this randomized, controlled trial in Phase I is to determine whether the Pillsy intervention can improve adherence to buprenorphine-naloxone compared to Service As Usual.
This will be a collaborative study between WSU, Pillsy, Inc, and the clinical site Ideal Option (opioid use and other substance use disorders treatment center). The overarching goal is to evaluate if the use of the Pillsy system will improve treatment adherence. The study coordinator will work closely with the clinical site, conducting a scripted screening, by phone or in person, documenting substance use, addiction treatment history, medical and psychiatric history, medication, addiction treatment goals, and availability of social support.
Dynamicare
Study on Alcohol Use Disorder (AUD) for Washington Medicaid Members
Ideal Option will offer contingency management through Dynamicare’s study on Alcohol Use Disorder (AUD) for Washington Medicaid members who meet study inclusion criteria. The NIH has provided DynamiCare a grant to do a full randomized controlled trial with patients to test Dynamicare’s effectiveness for AUD. Patients get randomized to either 12 months of full DynamiCare or 12 months of control group (compensation for submitting remote substance tests).
Publications and Presentations
Long-term buprenorphine treatment for kratom use disorder: A case series
Viktoriya R. Broyan, Jessica K. Brar, Tristen Allgaier, Student & Jeffrey T. Allgaier (2022) Long-term buprenorphine treatment for kratom use disorder: A case series, Substance Abuse, 43:1, 763-766. Read the Study
Provider Reactions to Opioid-Prescribing Report Cards
Alishahi, Musheng L. MS; Olson, Katie MPH; Brooks-Russell, Ashley PhD, MPH; Hoppe, Jason DO; Runyan, Carol PhD, MPH Provider Reactions to Opioid-Prescribing Report Cards, Journal of Public Health Management and Practice: May 13, 2021 - Volume Publish Ahead of Print - Issue - DOI: Read the Study
The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area
Calcaterra, S. L., Butler, M., Olson, K., & Blum, J. (2021). The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area. Journal of addiction medicine, Advance online publication. Read the Study
Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series
Brar, Jessica K. BS; Broyan, Viktoriya R. MS; Allgaier, Jeffrey T. MD, FACEP, FASAM; Nye, Larry PA-C; Saxon, Andrew J. MD Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series, Journal of Addiction Medicine: November/December 2020 - Volume 14 - Issue 6 - p e378-e381 Read the Study
Definitive urine drug testing in office-based opioid treatment: a literature review
Andrea G. Barthwell, Jeffrey Allgaier & Kenneth Egli (2018) Definitive urine drug testing in office-based opioid treatment: a literature review, Critical Reviews in Toxicology, 48:10, 815-838, DOI: Read the Study
Patient Feedback on a Mobile Medication Adherence Platform for Opioid Relapse Prevention
Smith, C.L., Keever, A., Bowden, T., Smoody, G., Olson, K., McDonell, M.G., Roll, J., McPherson, S. (May 2022) Patient Feedback on a Mobile Medication Adherence Platform for Opioid Relapse Prevention. Poster to be presented at the Society for Prevention Research 30th Annual Meeting, Seattle, WA.
Bringing Transparency to Treatment: Evaluation of Patient Outcomes.
Dawson, B., Olson, K. (April 2022). Bringing Transparency to Treatment: Evaluation of Patient Outcomes. Poster to be presented at the RxSummit conference, Atlanta, GA.
Bridging the Gap between Incarceration and Treatment for Individuals with Opioid Use Disorder in Benton County, Washington.
Combs, J., Dawson, B., Roberts, A. (November 2020). Bridging the Gap between Incarceration and Treatment for Individuals with Opioid Use Disorder in Benton County, Washington. Virtual presentation at National Commission on Correctional Health Care Conference.
Use of QTOF to Detect Novel Psychoactive Substances in Patients Receiving Treatment for Substance Use Disorder
Figueroa, D, He, K and Newcombe, DA. (May 2022). Use of QTOF to Detect Novel Psychoactive Substances in Patients Receiving Treatment for Substance Use Disorder. Poster presentation given by D. Newcombe at the 2022 Mass Spectrometry in the Clinical Laboratory Conference, Monterey, CA.